Thymosin increases production of T-cell growth factor by normal human peripheral blood lymphocytes.
Zatz. M M MM; Oliver. J J; Samuels. C C; Skotnicki. A B AB; Sztein. M B MB; Goldstein. A L AL
Key Findings
- Thymosin increases T‑cell growth factor production in phytohemagglutinin‑stimulated lymphocytes
- The boost is dose‑dependent and strongest within the first 24 hours
- The activity isn’t due to thymosin‑alpha‑1, suggesting other components in fraction 5 are responsible
Practical Outcomes
- Thymosin could be a useful immune‑support tool, but you’d likely need an activated immune state for it to work. No clear dosing or protocol emerges from this study, so more human research is needed before practical use.
Summary
In lab tests, adding thymosin to already‑stimulated immune cells made them produce more of a growth factor that helps T‑cells, especially in the first day, but the effect isn’t caused by the well‑known piece called thymosin‑alpha‑1. This hints that thymosin mixes might boost immunity, though we don’t yet know how to use it in people.
Abstract
The in vitro incubation of phytohemagglutinin-stimulated peripheral blood lymphocytes with thymosin results in a marked and reproducible increase in production of T-cell growth factor, which is dose dependent and most pronounced in the first 24 hr of culture. Incubation of lymphocytes with thymosin alone failed to induce any production of T-cell growth factor. The biological activity of thymosin fraction 5 cannot be attributed to the activity of thymosin alpha 1, one of the well-characterized peptide components of fraction 5. These data provide the basis for (i) a potential mechanism for the in vivo immunorestorative effects of thymosin in primary and secondary immunodeficiencies and (ii) identification of an additional, but as yet undefined, immunoregulatory component of thymosin fraction 5.
Study Information
pubmed
1984
10.1073/pnas.81.9.2882